Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05885555 · ClinicalTrials.gov registry record · Phase 2
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
A Phase 2 study of Primary Immune Thrombocytopenia (ITP), sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 20
- Study locations
NCT05885555 is a Phase 2 study of Primary Immune Thrombocytopenia (ITP) that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 41 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT05885555, a Phase 2 study of Primary Immune Thrombocytopenia (ITP), is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the therapeutic efficacy, safety and tolerability of ianalumab in adult patients with primary ITP previously treated with at least one corticosteroid and one TPO-RA.
Conditions Studied
Interventions
- BIOLOGICAL Ianalumab
Study Locations (20)
Other
- Novartis Investigative Site - CABA
- Novartis Investigative Site - Beijing
- Novartis Investigative Site - Jinan
- Novartis Investigative Site - Toulouse
- Novartis Investigative Site - Giessen
- Novartis Investigative Site - Johor Bahru
- Novartis Investigative Site - Katowice
- Novartis Investigative Site - Seoul
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Med Center - Boston
Australian Capital Territory
- Novartis Investigative Site - Garran
Victoria
- Novartis Investigative Site - Melbourne
Hubei
- Novartis Investigative Site - Wuhan
Saxony
- Novartis Investigative Site - Dresden
Thuringia
- Novartis Investigative Site - Jena
TO
- Novartis Investigative Site - Torino
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2023-08-16 |
| Est. Completion | 2029-03-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05885555
The ClinicalTrials.gov registry entry for NCT05885555 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Immune Thrombocytopenia (ITP) appearing as the primary indexed condition, and to 1 intervention - of which Ianalumab is the first listed.
NCT05885555 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Massachusetts, Australian Capital Territory.
Frequently Asked Questions
What is clinical trial NCT05885555 about?
NCT05885555 is a clinical study titled "A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies". The purpose of this study is to evaluate the therapeutic efficacy, safety and tolerability of ianalumab in adult patients with primary ITP previously treated with at least one corticosteroid and one TPO-RA.
What is the current status of trial NCT05885555?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2023-08-16. Estimated completion is 2029-03-19.
What conditions does trial NCT05885555 study?
This clinical trial studies the following conditions: Primary Immune Thrombocytopenia (ITP).
What interventions are being tested in trial NCT05885555?
The interventions under investigation include: Ianalumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05885555?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05885555 being conducted?
This trial has 20 study locations across Massachusetts, Australian Capital Territory, Victoria, Hubei, Saxony. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Immune Thrombocytopenia (ITP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.